Plain-English translation of NCT06508983 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new drug called SG301 to see if it works better than a placebo (dummy pill) when combined with two existing myeloma medications— and . You would be in this trial if your multiple myeloma has come back or stopped responding to previous treatments, even after trying other standard therapies. Researchers want to find out if adding this new medication to your current treatment plan can help control your disease better.
Multiple myeloma can become resistant to standard treatments over time, leaving patients with limited options. This trial exists to see whether this new medication might offer hope to patients whose cancer has stopped responding to earlier drug combinations.
You likely qualify if…
You likely don't qualify if…
The trial has two stages. In Stage 1, researchers figure out the best dose of the new medication. In Stage 2, you would be randomly assigned to receive either the new drug combined with and , or a placebo combined with the same two medications. You would take these treatments in 28-day cycles and continue until your disease progresses, you experience unacceptable side effects, or your doctor decides to stop treatment. You'll need regular check-ins with your medical team to monitor how you're responding.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
China